Search

Search Constraints

You searched for: Author/Creator Dirven, Clemens

Search Results

1. 883 Impact of Awake Craniotomy within Eloquent Glioblastoma Subgroups (GLIOMAP): A Propensity-Score Matched Analysis of an International, Multicenter, Cohort Study. (April 2023)

2. Characterisation of vasodilatory responses in the presence of the CGRP receptor antibody erenumab in human isolated arteries. (December 2019)

3. ITVT-10. Using functional Ultrasound (fUS) for real-time, depth-resolved functional and vascular delineation of brain tumors with micrometer-millisecond precision. (12th November 2021)

4. Low-dose oncolytic adenovirus therapy overcomes tumor-induced immune suppression and sensitizes intracranial gliomas to anti-PD-1 therapy. Issue 1 (3rd February 2020)

5. Low-dose oncolytic adenovirus therapy overcomes tumor-induced immune suppression and sensitizes intracranial gliomas to anti-PD-1 therapy. Issue 2 (3rd February 2020)

6. NIMG-75. WHO 2016 GRADE II GLIOMA MOLECULAR SUBTYPES HAVE A DISTINCT SPATIAL DISTRIBUTION PATTERN. (5th November 2018)

7. SURG-07. BETWEEN-HOSPITAL VARIATION IN MORTALITY AND SURVIVAL AFTER GLIOBLASTOMA SURGERY. (5th November 2018)

8. SURG-30. CLINICAL COURSE OF IDH-MUTATED LOW-GRADE GLIOMAS DURING THE POSTSURGICAL ACTIVE MONITORING PHASE: ASYMPTOMATIC PATIENTS, WELL CONTROLLED SEIZURES, BUT CONTINUOUS GROWTH OF TUMOR RESIDUES. (11th November 2019)

9. TMOD-19. FROM PATIENT TO PETRI DISH: INCREASING PATIENT-DERIVED GLIOBLASTOMA CULTURE EFFICIENCIES TO 95%. (12th November 2021)

10. TMOD-25. MODELING IDH1-MUTATED GLIOMAS: GENERATION, CHARACTERIZATION AND THERAPEUTIC SENSITIVITIES OF SEVEN PATIENT-DERIVED IDH1-MUTANT GLIOMA CELL LINES. (5th November 2018)